2023
Comparison of lower extremity bypass and peripheral vascular intervention for chronic limb-threatening ischemia in the Medicare-linked Vascular Quality Initiative
Cleman J, Romain G, Grubman S, Guzman R, Smolderen K, Mena-Hurtado C. Comparison of lower extremity bypass and peripheral vascular intervention for chronic limb-threatening ischemia in the Medicare-linked Vascular Quality Initiative. Journal Of Vascular Surgery 2023, 78: 745-753.e6. PMID: 37207790, PMCID: PMC10964324, DOI: 10.1016/j.jvs.2023.05.015.Peer-Reviewed Original ResearchConceptsChronic limb-threatening ischemiaLower extremity bypassPeripheral vascular interventionsVascular Quality InitiativeLimb-threatening ischemiaCause mortalityRisk of deathExtremity bypassVascular interventionsQuality InitiativeCox proportional hazards regressionKaplan-Meier survival curvesProportional hazards regressionOverall mean ageLogistic regression modelsComparative effectiveness researchKnee poplitealMedicare registryInfrapopliteal arteriesHazards regressionMean ageThirty-dayHispanic ethnicityOutcome dataTreatment groupsDrug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsCommunity distress and risk of adverse outcomes after peripheral vascular intervention
Schenck C, Strand E, Smolderen K, Romain G, Nagpal S, Cleman J, Blume P, Mena-Hurtado C. Community distress and risk of adverse outcomes after peripheral vascular intervention. Journal Of Vascular Surgery 2023, 78: 166-174.e3. PMID: 36944389, PMCID: PMC11146282, DOI: 10.1016/j.jvs.2023.03.027.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsDistressed Communities IndexMajor amputationRisk of mortalityAdverse outcomesVascular interventionsVascular Quality Initiative databaseDCI scoresCommunity distressCox regression modelTime-dependent receiverCharacteristic curve analysisClinical characteristicsFinal cohortPrimary outcomeClinical outcomesCardiovascular diseasePatientsAmputationZip code dataMortalityRisk categoriesCurve analysisInitiative databaseOutcomesGuideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, Henke P, Sedrakyan A, Mena-Hurtado C. Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC Cardiovascular Interventions 2023, 16: 332-343. PMID: 36792257, PMCID: PMC10359106, DOI: 10.1016/j.jcin.2022.09.022.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyPeripheral vascular interventionsMedical therapyVascular interventionsEnzyme inhibitors/angiotensin receptor blockersVascular Quality Initiative registryAngiotensin receptor blockersLong-term mortalityRisk of amputationRisk of mortalityNational quality registryQuality improvement effortsAmputation outcomesAmputation riskMajor amputationAntiplatelet therapyCause mortalityReceptor blockersMean ageVascular careQuality registryObservational studyMortality riskHigh riskAmputation data
2022
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classification
2013
Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry
Smolderen KG, Spertus JA, Tang F, Oetgen W, Borden WB, Ting HH, Chan PS. Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry. Journal Of The American College Of Cardiology 2013, 61: 1069-1075. PMID: 23375933, PMCID: PMC3641586, DOI: 10.1016/j.jacc.2012.11.058.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAmbulatory CareAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDrug UtilizationFemaleHumansHypolipidemic AgentsInsurance, HealthMaleMedicaidMedically UninsuredMedicareMiddle AgedPlatelet Aggregation InhibitorsRegistriesUnited StatesUnited States Department of Veterans AffairsUnited States Indian Health ServiceConceptsCoronary artery diseaseUninsured patientsEvidence-based treatmentsInsurance statusARB therapyAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersEnzyme inhibitors/angiotensin II receptor blockersAngiotensin II receptor blockersNational Cardiovascular Data RegistryPublic insuranceEvidence-based medicationsLipid-lowering therapyII receptor blockersLeft ventricular dysfunctionHealth insuranceTreatment differencesPoisson regression modelsPINNACLE RegistryPhysician adherenceVentricular dysfunctionReceptor blockersArtery diseaseCardiac RegistryCardiac outpatientsData registry